## Colfax

2Q 2009 Earnings Call

August 4, 2009

The following information contains forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Colfax's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forwardlooking statements are based on Colfax's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Colfax's results to differ materially from current expectations include, but are not limited to factors detailed in Colfax's reports filed with the U.S. Securities and Exchange Commission as well as its Annual Report on Form 10-K under the caption "Risk Factors". In addition, these statements are based on a number of assumptions that are subject to change. This presentation speaks only as of this date. Colfax disclaims any duty to update the information herein.


- Adjusted net income of $\$ 8.5$ million (20 cents per share) compared to $\$ 13.9$ million (32 cents per share) in Q2 2008, including negative currency effects of 4 cents per share
- Net sales of $\$ 129.2$ million compared to $\$ 161.4$ million in Q2 2008, a decrease of 20.0\% (organic decline of 10.2\%)
- Adjusted operating income of $\$ 14.3$ million compared to $\$ 23.6$ million in Q2 2008, including negative currency effects of $\$ 2.3$ million
- Adjusted EBITDA of $\$ 17.8$ million compared to $\$ 27.5$ million in Q2 2008, including negative currency effects of $\$ 2.6$ million
- Second quarter orders of $\$ 104.1$ million compared to $\$ 188.8$ in Q2 2008, a decrease of 44.9\% (organic decline of 38.3\%)
- Backlog of $\$ 292.3$ million


## Colfax

-Lower Results for Q2 2009

- Organic sales down $10 \%$ year over year, down $8 \%$ sequentially
- Results impacted by reduced OEM demand and push-out of project deliveries
- Organic sales increased in commercial marine (up 7\%) and global navy (up 26\%)
-Global Business Conditions Continued to Weaken in Q2
- Organic orders declined $38 \%$ year-over-year, down $17 \%$ sequentially
- Decline driven by commercial marine (down 54\%) and general industrial (down 44\%)

Decline in commercial marine orders includes cancellations of $\$ 9$ million
Weakness in most general industrial submarkets including chemical, distribution, machinery support and building products

- Adjusted net income of $\$ 18.9$ million (44 cents per share) compared to $\$ 24$ million (55 cents per share) in 2008, including negative currency effects of 9 cents per share
- Net sales of $\$ 265.5$ million compared to $\$ 292.1$ million in 2008 , a decrease of $9.1 \%$ (organic growth of 2.4\%)
- Adjusted operating income of $\$ 31.4$ million compared to $\$ 41.9$ million in 2008, including negative currency effects of $\$ 5.6$ million
- Adjusted EBITDA of $\$ 38.3$ million compared to $\$ 49.5$ million in 2008 , including negative currency effects of $\$ 6.2$ million
- Orders of $\$ 224.9$ million compared to $\$ 369.1$ million in 2008, a decrease of $39.1 \%$ (organic decline of 32.0\%)
-Continuing to rightsize to align capacity with demand
-Major actions since the beginning of the year:
- Reduced temporary, contract and full-time employees (approximately 150 associates)
- Implemented furlough programs in Germany (approximately 628 associates, 100 full-time equivalents)
- Closed facility in Aberdeen, NC
- Announced closing of Sanford, NC facility
-Expect savings of about $\$ 13$ million in 2009, including furlough-related savings
-Expect restructuring expenses of about $\$ 4$ million in 2009 for activities announced to date
-Additional restructuring anticipated as year progresses
-Will remain agile and respond as conditions warrant
-CBS activity continues in all areas

(1) Refer to Appendix for Non-GAAP reconciliation


## Colfax Orders and Backlog



## Colfax Q2 2009 Sales and Orders by End Market



## Colfax



- Strong balance sheet
- Debt to adjusted EBITDA = 1
- Debt of $\$ 94$ million, principal payments of $\$ 5$ million in 2009, matures in 2013
- Cash = \$38 million
- \$136 million available on revolver
-Strong cash flow
- Adjusted EBITDA (LTM) of $\$ 94$ million

|  | Three Months Ended |  |  |  | Delta |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 7/3/2009 |  | 6/27/2008 |  |  | \$ | \% |
| Orders | \$ | 104.1 | \$ | 188.8 | \$ | (84.7) | (44.9)\% |
| Sales | \$ | 129.2 | \$ | 161.4 | \$ | (32.2) | (20.0)\% |
| Gross Profit \% of Sales | \$ | $\begin{gathered} 44.6 \\ 34.5 \% \end{gathered}$ | \$ | $\begin{gathered} 56.8 \\ 35.2 \% \end{gathered}$ | \$ | (12.2) | (21.5)\% |
| Adjusted SG\&A Expenses | \$ | 28.6 | \$ | 31.6 | \$ | (3.1) | (9.7)\% |
| R\&D Expense |  | 1.7 |  | 1.6 |  | 0.1 | 6.9\% |
| Operating Expenses \% of Sales | \$ | $\begin{gathered} \hline 30.3 \\ 23.4 \% \end{gathered}$ | \$ | $\begin{gathered} \hline 33.2 \\ 20.6 \% \end{gathered}$ | \$ | (3.0) | (8.9)\% |
| Adjusted Operating Income \% of Sales | \$ | $\begin{gathered} 14.3 \\ 11.1 \% \end{gathered}$ | \$ | $\begin{gathered} 23.6 \\ 14.6 \% \end{gathered}$ | \$ | (9.3) | (39.4)\% |
| Adjusted EBITDA \% of Sales | \$ | $\begin{gathered} 17.8 \\ 13.8 \% \end{gathered}$ | \$ | $\begin{gathered} 27.5 \\ 17.0 \% \end{gathered}$ | \$ | (9.7) | (35.2)\% |
| Adjusted Net Income \% of Sales | \$ | $\begin{gathered} 8.5 \\ 6.6 \% \end{gathered}$ | \$ | $\begin{aligned} & 13.9 \\ & 8.6 \% \end{aligned}$ | \$ | (5.4) | (38.8)\% |

Refer to Appendix for Non-GAAP reconciliation.

|  | Six Months Ended |  |  |  | Delta |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | 7/3/2009 |  | 6/27/2008 |  |  | \$ | \% |
| Orders | \$ | 224.9 | \$ | 369.1 |  | 144.2) | (39.1)\% |
| Sales | \$ | 265.5 | \$ | 292.1 | \$ | (26.6) | (9.1)\% |
| Gross Profit \% of Sales | \$ | $\begin{gathered} 92.6 \\ 34.9 \% \end{gathered}$ | \$ | $\begin{aligned} & 105.0 \\ & 35.9 \% \end{aligned}$ | \$ | (12.4) | (11.8)\% |
| Adjusted SG\&A Expense | \$ | 58.1 | \$ | 60.2 | \$ | (2.0) | (3.4)\% |
| R\&D Expense |  | 3.1 |  | 3.0 |  | 0.1 | 4.6\% |
| Operating Expenses \% of Sales | \$ | $\begin{gathered} \hline 61.2 \\ 23.1 \% \end{gathered}$ | \$ | $\begin{gathered} \hline 63.1 \\ 21.6 \% \end{gathered}$ | \$ | (1.9) | (3.0)\% |
| Adjusted Operating Income \% of Sales | \$ | $\begin{gathered} 31.4 \\ 11.8 \% \end{gathered}$ | \$ | $\begin{gathered} 41.9 \\ 14.3 \% \end{gathered}$ | \$ | (10.5) | (25.0)\% |
| Adusted EBITDA \% of Sales | \$ | $\begin{gathered} 38.3 \\ 14.4 \% \end{gathered}$ | \$ | $\begin{gathered} 49.5 \\ 16.9 \% \end{gathered}$ | \$ | (11.2) | (22.7)\% |
| Adjusted Net Income \% of Sales | \$ | $\begin{aligned} & 18.9 \\ & 7.1 \% \end{aligned}$ | \$ | $\begin{aligned} & 24.0 \\ & 8.2 \% \end{aligned}$ | \$ | (5.2) | (21.5)\% |



## Colfax



| Assumptions |  |
| :--- | :--- |
| Asbestos coverage litigation | $\$ 12$ million |
| Asbestos liability and defense costs | $\$ 7$ million |
| Euro | $\$ 1.41$ |
| Tax rate | $32 \%$ |
| Interest expense | $\$ 8$ million |
| Incremental public company costs | $\$ 2.5$ million |
| Outstanding shares | 43.3 million |

(1) Excludes impact of foreign exchange rate fluctuations
(2) Excludes impact of asbestos coverage litigation, asbestos liability and defense costs, and restructuring and other related charges (See Appendix for Non-GAAP reconciliation)

## Colfax



## Appendix

Adjusted net income, adjusted net income per share, adjusted operating income and adjusted EBITDA exclude asbestos liability and defense costs (income) and asbestos coverage litigation expenses, certain legacy legal charges, certain due diligence costs, restructuring and other related charges as well as one time initial public offering-related costs to the extent they impact the periods presented. Adjusted selling, general and administrative expenses exclude legacy legal adjustments. Adjusted net income also reflects interest expense as if the initial public offering (IPO) had occurred at the beginning of 2007 and presents income taxes at an effective tax rate of $\mathbf{3 2 \%}$ in 2009 and $34 \%$ in 2008. Adjusted net income per share in 2008 assumes the 44,006,026 shares outstanding at the closing of the IPO to be outstanding since January 1, 2007. Projected adjusted net income per share excludes actual and estimated restructuring and other related charges, asbestos coverage litigation expenses and asbestos liability and defense costs. Organic sales growth (decline) and organic order growth (decline) exclude the impact of foreign exchange rate fluctuations. These non-GAAP financial measures assist Colfax in comparing its operating performance on a consistent basis because, among other things, they remove the impact of changes in our capital structure and asset base, non-recurring items such as IPO-related costs, legacy asbestos issues (except in the case of EBITDA) and items outside the control of its operating management team.

Sales and order information by end market are estimates. We periodically update our customer groupings in order to refine these estimates. During 2009, reclassifications of previously reported amounts were made to conform to current period presentation. No changes have been made to total sales or orders.

## Colfax

|  | Three Months Ended |  |  |  | Six Months Ended |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | July 3, 2009 |  | June 27, 2008 |  | July 3, 2009 |  | June 27, 2008 |  |
| EBITDA |  |  |  |  |  |  |  |  |
| Net income (loss) | \$ | 4,366 | \$ | $(31,399)$ | \$ | 11,227 | \$ | $(24,601)$ |
| Interest expense |  | 1,786 |  | 3,236 |  | 3,632 |  | 7,733 |
| Provision (benefit) for income taxes |  | 2,142 |  | $(12,679)$ |  | 5,245 |  | $(9,101)$ |
| Depreciation and amortization |  | 3,538 |  | 3,955 |  | 6,911 |  | 7,650 |
| EBITDA | \$ | 11,832 | \$ | $(36,887)$ | \$ | 27,015 | \$ | $(18,319)$ |
| EBITDA margin |  | 9.2\% |  | (22.9)\% |  | 10.2\% |  | (6.3)\% |
| Adjusted EBITDA |  |  |  |  |  |  |  |  |
| Net income (loss) | \$ | 4,366 | \$ | $(31,399)$ | \$ | 11,227 | \$ | $(24,601)$ |
| Interest expense |  | 1,786 |  | 3,236 |  | 3,632 |  | 7,733 |
| Provision for income taxes |  | 2,142 |  | $(12,679)$ |  | 5,245 |  | $(9,101)$ |
| Depreciation and amortization |  | 3,538 |  | 3,955 |  | 6,911 |  | 7,650 |
| Restructuring and other related charges |  | 486 |  | - |  | 1,147 |  | - |
| IPO-related costs |  | - |  | 57,017 |  | - |  | 57,017 |
| Legacy legal adjustment |  | - |  | 4,131 |  | - |  | 4,131 |
| Asbestos liability and defense costs (income) |  | 1,482 |  | (715) |  | 3,127 |  | (437) |
| Asbestos coverage litigation expense |  | 4,027 |  | 3,970 |  | 6,993 |  | 7,109 |
| Adjusted EBITDA | \$ | 17,827 | \$ | 27,516 | \$ | 38,282 | \$ | 49,501 |
| Adjusted EBITDA margin |  | 13.8\% |  | 17.0\% |  | 14.4\% |  | 16.9\% |

## Colfax non-gAAP Reconciliation



$\square$ Tusuace


|  | Sales |  |  | Orders |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  |  | \$ | \% | \$ |  | \% |
| Three Months Ended June 27, 2008 | \$ | 161.4 |  |  | 188.8 |  |
| Components of Growth: |  |  |  |  |  |  |
| Existing Businesses |  | (16.4) | (10.2)\% |  | (72.3) | (38.3)\% |
| Foreign Currency Translation |  | (15.8) | (9.8)\% |  | (12.4) | (6.6)\% |
| Total Growth |  | (32.2) | (20.0)\% |  | (84.7) | (44.9)\% |
| Three Months Ended July 3, 2009 | \$ | 129.2 |  | \$ | 104.1 |  |

## Six Months Ended June 27, 2008

Components of Growth:
Existing Businesses
Foreign Currency Translation

Total Growth

Six Months Ended July 3, 2009

\$ 292.1


Adjusted SG\&A Expense
Selling, general and administrative expenses

Legacy legal adjustment

Adjusted selling, general and administrative expenses

| Three Months Ended |  |  |  | Six Months Ended |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| July 3, 2009 |  | June 27, 2008 |  | July 3, 2009 |  | June 27, 2008 |  |
| \$ | 28,586 | \$ | 35,776 | \$ | 58,112 | \$ | 64,283 |
|  | - |  | 4,131 | - |  |  | 4,131 |
| \$ | 28,586 | \$ | 31,645 | \$ | 58,112 | \$ | 60,152 |
|  | 22.1\% |  | 19.6\% |  | 1.9 |  | 20.6\% |

Non-GAAP Reconciliation

## Colfax Corporation

## Reconciliation of Projected 2009 Net Income Per Share to Adjusted Net Income Per Share

Amounts in Dollars

## (unaudited)

|  | EPS Range |  |  |
| :--- | ---: | ---: | ---: |
|  |  |  |  |
| Projected net income per share - fully diluted | $\$$ | 0.57 | $\$$ |
|  |  | 0.64 |  |
| Actual first half restructuring and other related charges |  | 0.02 |  |
| Estimated second half restructuring and other related charges |  | 0.04 | 0.02 |
| Asbestos coverage litigation | 0.19 | 0.04 |  |
| Asbestos liability and defense costs |  | 0.11 | 0.11 |
| Projected adjusted net income per share - fully diluted | $\$$ | 0.93 | $\$$ |

